Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Amsterdam  >  Royal Philips    PHIA   NL0000009538

ROYAL PHILIPS

(PHIA)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Royal Philips : Tariffs take toll on Philips margin goal in blow to shares

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/10/2019 | 05:01am EDT
FILE PHOTO: Dutch health technology company Philips presents the company's financial results for the fourth quarter in Amsterdam

AMSTERDAM (Reuters) - Philips warned it will miss its 2019 profit margin target on Thursday due to trade tariffs and poor results at its Connected Care arm, wiping around 3 billion euros ($3.3 billion)off the Dutch healthcare technology group's market value.

The trade war between the United States and China has forced Philips to shift production and to seek other suppliers for components in recent months to avoid punitive tariffs.

But this has proved harder to achieve than earlier expected, while tariffs rose faster than previously announced, Chief Executive Frans van Houten told reporters.

"Tariffs have gone up, definitions have become clearer", Van Houten said, adding: "The impact has gone up, while mitigating actions have been delayed."

Philips shares were down 8% at 0820 GMT after the warning.

Earlier this year, Philips said the trade war between Washington and Beijing was forcing it to move hundreds of millions of euros worth of production from the U.S. to China, and vice versa, to avoid tariffs.

These mainly hurt Philips' connected care business, which specialises in remote patient monitoring, for instance through software platforms and devices that allow doctors to share patient information.

Sales of connected care were 3 billion euros ($3.3 billion) last year, on total group revenues of 18.1 billion euros.

The connected care arm is more exposed to trade tariffs than Philips' two larger businesses, which make hospital equipment such as medical scanners and personal health products such as toothbrushes, as it offers many more and smaller products.

"This means we need a lot of small actions, which all add up", Van Houten said.

"In diagnosis & treatment we have fewer products, while in personal health the volumes are higher, so a single action there has greater effect on the whole."

MARGIN GOAL MISS

Margins at the struggling Connected Care division not only dropped in the third quarter as tariffs hit, but also because factories lowered production to get rid of high inventories.

Philips has repeatedly said rising life expectancy and associated chronic diseases would lead to growing demand for devices that allow patients to stay at home, while their data is monitored.

But Van Houten last year also said demand for such products would remain modest in 2019.

Philips now expects its adjusted EBITA margin to only improve by 10 to 20 basis points this year, well off its previous 100 basis point goal.

"Based on this profit warning we expect 2019 adjusted EBITA to come down by low-to-mid-single digit", ING analyst Marc Hesselink said.

Philips did stick to its target of improving comparable sales by 4% to 6% this year, as Van Houten said he continued to see good growth in all his businesses.

Preliminary third quarter results, also released on Thursday, showed sales are expected to have increased 6% in the quarter to 4.7 billion euros, while adjusted earnings before tax, interest and amortisation (EBITA) increased 3% to 583 million euros.

A 78 million euros impairment on connected care pushed net profit down around 30% to 210 million euros.

(Reporting by Bart Meijer; Editing by Muralikumar Anantharaman and Alexander Smith)

By Bart H. Meijer

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ROYAL PHILIPS
04:00aPhilips and Klinikum Stuttgart hospital sign 10-year innovation partnership a..
GL
03:19aROYAL PHILIPS : Philips retains its top-50 best global brand ranking
PU
10/17Philips extends AI capabilities for high acuity virtual care venues with laun..
GL
10/16ROYAL PHILIPS : VFW Post 6786 First Site in Innovative Initiative Giving Veteran..
BU
10/15Eaton to Sell Lighting Business to Signify in $1.4 Billion Deal
DJ
10/15ROYAL PHILIPS : Why the Internet of Things in healthcare is really about people,..
PU
10/15ROYAL PHILIPS : Philips introduces new 200mm and 150mm Stellarex 0.035' low-dose..
AQ
10/15ROYAL PHILIPS : Philips introduces new 200mm and 150mm Stellarex 0.035” lo..
AQ
10/15AIRPORT SMART LIGHTING MARKET IS TOU : Koninklijke Philips, Osram, Schreder, Hel..
AQ
10/14ROYAL PHILIPS : Philips highlights importance of 6-minute ‘time-to-defib' ..
PU
More news
Financials (EUR)
Sales 2019 19 493 M
EBIT 2019 2 459 M
Net income 2019 1 421 M
Debt 2019 3 558 M
Yield 2019 2,21%
P/E ratio 2019 25,8x
P/E ratio 2020 20,8x
EV / Sales2019 1,98x
EV / Sales2020 1,86x
Capitalization 35 117 M
Chart ROYAL PHILIPS
Duration : Period :
Royal Philips Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROYAL PHILIPS
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 44,38  €
Last Close Price 39,07  €
Spread / Highest target 38,0%
Spread / Average Target 13,6%
Spread / Lowest Target -10,4%
EPS Revisions
Managers
NameTitle
Frans van Houten Chief Executive Officer
Jeroen van der Veer Chairman-Supervisory Board
Sophie Bechu Chief Operating Officer & Executive Vice President
Abhijit Bhattacharya Chief Financial Officer & Executive Vice President
Jan Kimpen Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
ROYAL PHILIPS26.32%39 058
THERMO FISHER SCIENTIFIC25.83%112 770
DANAHER CORPORATION33.60%98 832
INTUITIVE SURGICAL, INC.10.54%61 015
BOSTON SCIENTIFIC CORPORATION8.01%53 170
EDWARDS LIFESCIENCES CORPORATION48.72%47 375